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Summary
INTRODUCTION: Clinical manifestations of hypertroph-
ic cardiomyopathy (HCM) range from asymptomatic dis-
ease to early-onset heart failure and sudden cardiac death
(SCD). Risk stratification for SCD remains imperfect and
novel risk markers are needed. The aim of our study was to
evaluate the association of elevated high-sensitivity cardi-
ac troponin T levels (hs-cTnT) with the severity of disease
expression and adverse events in patients with HCM.
METHODS: All patients followed-up at a dedicated HCM
clinic at a tertiary care centre between April 2012 and
March 2014 were analysed. The clinical care track for these
patients includes 12-lead ECG, blood work-up, echocardi-
ography, Holter ECG, exercise stress testing and cardiovas-
cular magnetic resonance imaging (CMR). Clinical data
were obtained from medical records.
RESULTS: Of 91 HCM patients (77% males, mean age at
follow up 51 ± 16 years), 46 (51%) had elevated hs-cTnT
levels (>0.014 ng/ml). Patients with elevated hs-cTnT
levels had greater maximum wall thickness (23 ± 7 mm vs
19 ± 3 mm, p = 0.001), more often had myocardial fibrosis
(96% vs 54%, p <0.001), and lower exercise capacity (90%
predicted vs 76% predicted, p = 0.002). There was a trend
towards lower event-free survival estimates (Kaplan-Meier
method, 15% vs 7%, p = 0.16).
CONCLUSIONS: Elevated hs-cTnT levels in HCM pa-
tients are associated with disease severity and, potentially,
with more adverse cardiac events. Future studies should
test whether integration of hs-cTnT in clinical decision al-
gorithms will improve risk stratification.
Key words: hypertrophic cardiomyopathy; troponin T;
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Introduction
Hypertrophic cardiomyopathy (HCM) is the most common
genetic cardiovascular disorder, affecting approximately
one in 500 people within the general population [1]. It is
defined as left ventricular hypertrophy in the absence of
another cardiac or systemic disease (e.g. arterial hyperten-
sion, aortic stenosis, metabolic cardiomyopathy) capable
of producing the magnitude of hypertrophy evident [2].
The natural course of HCM varies widely. Some affected
patients remain completely asymptomatic throughout life,
while others develop progressive heart failure early in life.
Apart from early onset heart failure, premature sudden car-
diac death (SCD) is the most feared complication. The av-
erage SCD rate in populations with HCM is 0.7% per year,
compared with 0.3% in the general population [3, 4]. Risk
stratification for SCD remains imperfect. Traditional mark-
ers for risk stratification include the extent of left ventricu-
lar hypertrophy, recent unexplained syncope, positive fam-
ily history of SCD, nonsustained ventricular tachycardia
and abnormal blood pressure response during exercise [2,
5]. More recently, the presence and extent of myocardi-
al fibrosis on cardiac magnetic resonance imaging (MRI)
was recognised as a predictor for arrhythmic events includ-
ing ventricular arrhythmias and atrial fibrillation, as well as
heart failure events [6–8]. Since the traditional risk factors
in combination with the assessment of myocardial fibrosis
with cardiac MRI cannot identify every patient at high risk,
the search for alternative risk factors is ongoing [9]. Sever-
al studies suggest that elevated biomarkers including car-
diac troponins may be associated with more severe dis-
ease expression and potentially adverse outcome in patients
with HCM, similar to patients with heart failure from other
causes [10–13].
The aim of our study therefore was to assess the prevalence
of elevated high-sensitivity cardiac troponin T (hs-cTnT)
levels in HCM patients followed-up at our tertiary referral
centre in Switzerland, and to assess the association of hs-
cTnT with disease severity and adverse cardiovascular out-
come.
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Methods
Patient population
In this retrospective study, we included all consecutive
patients with HCM seen at our outpatient clinic between
April 2012 and March 2014. The mean follow-up from
initial diagnosis was 11.5 years (range 0.5–35 years). Pa-
tients were diagnosed with HCM based on echocardio-
graphic findings with left ventricular hypertrophy (maxim-
um wall thickness ≥15 mm) in the absence of other cardiac
or systemic disorders capable of producing the magnitude
of hypertrophy evident [2]. Patients with significant ren-
al impairment (serum creatinine >260 μmol/l) and coron-
ary artery disease were excluded. In patients who presented
with cardiovascular risk factors and symptoms consistent
with coronary heart disease (n = 53), we performed either
a coronary angiogram or a coronary computed tomography
scan to rule out coronary heart disease.
All patients underwent routine assessment according to our
clinical care track including physical examination, 12-lead
electrocardiogram (ECG), routine blood work up, 24–48
hours Holter ECG (presence of nonsustained ventricular ta-
chycardias), and symptom-limited exercise stress testing.
Abnormal haemodynamic response was defined as a blood
pressure drop or abnormal increase of systolic blood pres-
sure of <20 mm Hg during exercise. All patients underwent
transthoracic echocardiography according to the European
and American Society of Echocardiography [14]. Left
ventricular outflow tract obstruction was defined from
continuous-wave Doppler echocardiography as a peak in-
stantaneous outflow gradient ≥30 mm Hg under resting or
provoked conditions. In all patients without contraindica-
tion, cardiovascular magnetic resonance imaging (CMR)
was performed, including assessment of myocardial
fibrosis.
Clinical follow-up data were obtained by review of medical
records. Special attention was paid to HCM-related events
including SCD as well as appropriate discharges by a previ-
ously inserted automated implantable cardioverter defibril-
lator (AICD), atrial fibrillation, development of heart fail-
ure (progression to New York Heart Association [NYHA]
class III or IV in the absence of left ventricular outflow
tract obstruction, left ventricular ejection fraction <50%),
stroke and syncope.
Measurement of hs-cTnT
Peripheral venous blood samples were routinely collected
during first patient visit. For measurement of hs-cTnT, the
commercially available Elektrochemiluminiszenz-Immun-
oassay on a cobas® 8000 modular analyser (Roche Dia-
gnostics Ltd., Rotkreuz, Switzerland) was used. An hs-
cTnT level >0.014 ng/ml was considered to be elevated,
according to the standards of our laboratory.
Cardiovascular magnetic resonance imaging
The test was ordered after an initial visit to our outpatient
clinic. Image acquisition was performed on a clinical 1.5
Tesla MR scanner (Philips Achieva, Best, The Nether-
lands). A dedicated five-element cardiac phased-array re-
ceiver coil was used for signal reception. Cine images were
acquired using an ECG-triggered breath-hold balanced
steady-state free precision sequence covering the whole
heart from the valve plane to the apex with a slice thickness
of 8mm without gap. The field of view was 450 x 400 mm.
Sequence parameters included spatial resolution of 2.1 x
1.8 mm, temporal resolution of 25 heart beats, flip angle of
60°, and repetition time/echo time 3.4/1.7 ms. For late gad-
olinium enhancement (LGE) imaging, image acquisition
was performed 10–15 minutes after injection of 0.2 mmol/
kg gadobutrol (Gadovist; Bayer Schering Pharma, Zurich,
Switzerland) contrast agent with 2D breath-held segmented
inversion-recovery sequence, acquired in the same orient-
ation as the cine steady-state free precision images. Quan-
tification of LGE was performed by manually adjusting a
greyscale threshold to define areas of visually identified
LGE [15]. These areas were then summed to generate a
total volume of LGE and expressed as a proportion of total
LV mass myocardium (%LGE).
Statistical analysis
Continuous and categorical data are expressed as mean ±
standard deviation (SD) or n (%), respectively. Compar-
isons of characteristics between groups (hs-cTnT negat-
ive versus hs-cTnT positive group) were made with un-
paired Student’s t-test, chi-squared test or Fisher’s exact
test where appropriate for continuous and categorical data.
A combined end-point for cardiovascular mortality and
morbidity included SCD (natural death due to cardiac
causes heralded by abrupt loss of consciousness within 1
hour of the onset of acute symptoms), survived SCD, ap-
propriate AICD discharge, heart failure events (hospitalisa-
tions for heart failure, progression to NYHA function class
III–IV in the absence of left ventricular outflow tract ob-
struction and development of left ventricular ejection frac-
tion <50%), and thromboembolic events. Event-free estim-
ates curves were calculated by means of the Kaplan-Meier
method, and the log-rank test was used for comparison.
A p-value <0.05 was considered statistically significant.
All calculations were performed using SPSS version 16.7
(SPSS, Inc., Chicago, Illinois, US).
Results
Overall, we included 91 consecutive patients in our study
cohort. We were able to collect clinical information includ-
ing 24–48-hour ECGs and exercise stress tests results for
all patients in the study population. In 61 patients (67%),
CMR data was available.
Baseline characteristics
Clinical characteristics and information from cardiac ima-
ging for the entire cohort, and with respect to the hs-cTnT
level, are outlined in table 1. The patients’ age range was
18–79 years, and 77% of patients were male. The hs-cTnT
range in the entire cohort was 0.001–0.806 ng/ml. Half of
the patients had elevated hs-cTnT levels (46/91, 51%). The
majority of the patients were in NYHA functional class I
or II (87%). The maximum wall thickness was 22 ± 6 mm.
Forty-two percent of the patients had left ventricular out-
flow tract obstruction. This could be managed with medic-
ation in three quarters of the affected patients, whereas 10/
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38 (26%) had to undergo invasive septal reduction proced-
ures (septal alcohol ablation and surgical myectomy).
Findings with respect to hs-cTnT level
Details are given in table 1. Patients with elevated hs-cTnT
levels did not differ in terms of age and symptoms accord-
ing to their NYHA functional class compared with those
with normal hs-cTnT levels. However, there were signific-
ant differences with respect to their exercise capacity and
their severity of disease expression. Patients with elevated
hs-cTnT had lower exercise capacity than those with nor-
mal values, had greater maximal wall thickness, and were
more likely to have myocardial fibrosis on CMR; for pa-
tient examples see figure 1.
The type and frequency of adverse cardiovascular events
are shown in table 2. The Kaplan-Meier survival estimates
for survival free of cardiovascular events (combined end-
point) are depicted in figure 2. Although patients with elev-
ated hs-cTnT levels had more events during follow-up, the
difference did not reach statistical significance (p = 0.16).
Discussion
Risk stratification in patients with HCM is still imperfect
and there is a constant aim to improve risk models. While
current risk models may appropriately identify those pa-
tients at highest risk, there remains a large group of patients
at intermediate risk for whom risk modifiers may signi-
ficantly influence clinical decision-making [5, 16]. Apart
from presence and degree of myocardial fibrosis on CMR
[6–8, 17, 18], biomarkers such as hs-cTnT are promising
novel targets for improved risk stratification.
The approach currently used for risk stratification in HCM
patients is imperfect and requires refinement [9]. Hence,
biomarkers may provide more insights in identifying pa-
tients at risk for SCD and heart failure.
In our study, we demonstrate that patients with increased
hs-cTnT levels have more severe disease expression. Their
maximum wall thickness was greater and all but one patient
(96%) showed LGE on CMR, whereas only half of the
patients (54%) with normal hs-cTnT levels had LGE on
CMR. Moreover, patients with increased hs-cTnT levels
Table 1: Baseline characteristics by hs-cTnT level.
Variable All
n = 91
hs-cTnT ≤0.014 ng/ml
n = 45
hs-cTnT >0.014 ng/ml
n = 46
p-value
Age at diagnosis (years, ± SD) 40 ± 18 43 ± 16 37 ± 19 0.09
Age at last follow-up (years ± SD) 51 ± 16 53 ± 15 49 ± 17 0.35
Body surface area (m2 ± SD) 1.9 ± 0.2 1.9 ± 0.2 1.9 ± 0.2 0.43
Male sex, n (%) 70 (77) 35 (78) 36 (78) 1.0
Creatinine (μmol/l ± SD) 85 ± 24 (27-189) 83 ± 19 86 ± 29 0.61
NYHA I/II/III/IV, % 44/43/13/0 47/44/9/0 41/41/18/0 0.49
Positive family history of SCD, n (%) 13 (14) 6 (13) 7 (15) 0.63
Non-sustained VTs, n (%) 26 (29) 10 (22) 16 (35) 0.25
Atrial fibrillation, n (%) 20 (22) 9 (20) 11 (24) 0.88
Stroke/thromboembolic events, n (%) 1 (1) 0 1 (2) 1.00
SCD/appropriate AICD discharge, n (%) 7 (8) 3 (7) 4 (9) 0.71
Exercise stress test
maximum exercise capacity (watt ± SD) 142 ± 54 153 ± 54 130 ± 52 0.05
% predicted exercise capacity (± SD) 83 ± 21 90 ± 19 76 ± 21 0.002
abnormal BP response, n (%) 11 (12) 3 (7) 8 (17) 0.11
Imaging data
Maximal wall thickness (mm ± SD) 21 ± 6 19 ± 3 23 ± 7 0.001
LV end-diastolic diameter (mm ± SD) 44 ± 6 44 ± 6 46 ± 6 0.74
Posterior wall thickness (mm ± SD) 10 ± 2 10 ± 2 11 ± 2 0.01
LV ejection fraction (% ± SD) 66 ± 8 66 ± 7 67 ± 9 0.77
Left atrial volume, indexed (ml/m2 ± SD) 48 ± 20 45 ± 18 50 ± 22 0.22
LVOT obstruction, n (%) 38 (42) 18 (40) 20 (43) 0.83
LGE present, n (%)* 43 (70) 20 (54) 23 (96) <0.001
LGE amount, % LV mass ± SD 8 ± 7 4 ± 1 9 ± 2 0.03
hs-cTnT = high-sensitive cardiac troponin T; NYHA = New York Heart Association; HCM = hypertrophic cardiomyopathy; SCD = sudden cardiac death; VT = ventricular
tachycardia; AICD = automated implanted cardiac defibrillator; BP = blood pressure; LV = left ventricle; LVOT = left ventricular outflow tract; LGE = late gadolinium
enhancement; SD = standard deviation
* Overall, 61 patients underwent CMR; 37 in the hs-cTnT negative group and 24 in the hs-cTnT positive group.
Table 2: Adverse cardiovascular events.
Events hs-cTnT ≤0.014 ng/ml
n = 45
hs-cTnT >0.014 ng/ml
n = 46
Stroke/thromboembolic events 0 1 (2%)
SCD/appropriate AICD discharge 3 (7%) 4 (9%)
Heart failure events 0 2 (4%)
Combined endpoint* 3 (7%) 7 (15%)
AICD = automated implantable cardioverter defibrillator; hs-cTnT = high-sensitive cardiac troponin T; SCD = sudden cardiac death
* SCD, appropriate AICD discharge, heart failure, thromboembolic events
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had lower physical exercise capacity compared with those
with normal levels.
In addition, we could show only a trend towards more
events in patients with elevated hs-cTnT levels, displayed
as Kaplan-Meier event-free estimates curves for the com-
bined event including SCD, survived SCD, appropriate
AICD discharge, heart failure events and thromboembolic
Figure 1
(A) Patient in NYHA functional class II with nonobstructive HCM
and a maximal wall thickness of 35 mm and elevated hs-cTnT level
(0.05 ng/ml). (B) Patient with obstructive HCM controlled with beta
blocker therapy, a maximal wall thickness of 19 mm and normal hs-
cTnT level. (C) Patient with nonobstructive HCM and a maximal
wall thickness of 22 mm. On CMR, patient shows extensive LGE
(17% of LV mass) in the anterior wall segments (*) along with an
elevated hs-cTnT level (0.031 ng/ml). (D) Patient with
nonobstructive HCM and a maximal wall thickness of 16 mm
without LGE on CMR and normal hs-cTnT level.
Ao = Aorta; CMR = cardiovascular magnetic resonance; HCM =
hypertrophic cardiomyopathy; hs-cTnT = high-sensitive cardiac
troponin T; IVS = interventricular septum; LA = left atrium; LGE =
late gadolinium enhancement; LV = left ventricle; NYHA = New York
Heart Association; RV = right ventricle
Figure 2
Kaplan-Meier analysis for estimation of event-free survival
according to elevated (red line) or normal (blue line) hs-cTnT levels.
Although patients with raised hs-cTnT levels showed a trend
towards more events, it did not reach statistical significance (p =
0.16).
events. However, this trend might become more significant
after a prolonged follow-up period and if the sample size
were larger. Our event rate for the entire population (ap-
proximately 1% per year) is in line with the results of
other studies in larger cohorts with HCM [7, 8]. Of course,
all these findings could be explained by factors related to
the more severe disease expression, such as greater max-
imum wall thickness, more myocardial fibrosis and more
severe diastolic dysfunction. However, the number of pa-
tients was too small to allow a thorough multivariate ana-
lysis. Nonetheless, other groups described similar findings,
showing that elevated hs-cTnT levels were associated with
more extensive left ventricular hypertrophy [10, 19], pres-
ence of myocardial fibrosis on CMR [11], more frequent
occurrence of atrial fibrillation [20], and adverse outcome
[13], which supports the assumption that elevated hs-cTnT
levels indicate more severe disease expression and worse
prognosis requiring closer follow-up of those patients.
In conclusion, risk assessment in patients with HCM re-
quires a multimodality approach and routinely includes
echocardiography, exercise stress testing, Holter ECG, and
CMR. According to our findings, confirming previous res-
ults of other groups, biomarkers should be an integrative
part of the routine work-up in HCM, prompting closer
follow-up of patients with elevated hs-cTnT levels along
with referral for further evaluation with CMR.
Limitations
One of the major limitations is the relatively small study
population, which made a thorough multivariate analysis
of outcome measures impossible. Since we started a spe-
ciality clinic for HCM only 3 years ago at our institution,
follow-up times were relatively short for most of our pa-
tients, which explains the small number of events. An eval-
uation of the trends of our findings should be performed in
a multicentre study.
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Figures (large format)
Figure 1
(A) Patient in NYHA functional class II with nonobstructive HCM and a maximal wall thickness of 35 mm and elevated hs-cTnT level (0.05 ng/
ml). (B) Patient with obstructive HCM controlled with beta blocker therapy, a maximal wall thickness of 19 mm and normal hs-cTnT level. (C)
Patient with nonobstructive HCM and a maximal wall thickness of 22 mm. On CMR, patient shows extensive LGE (17% of LV mass) in the
anterior wall segments (*) along with an elevated hs-cTnT level (0.031 ng/ml). (D) Patient with nonobstructive HCM and a maximal wall
thickness of 16 mm without LGE on CMR and normal hs-cTnT level.
Ao = Aorta; CMR = cardiovascular magnetic resonance; HCM = hypertrophic cardiomyopathy; hs-cTnT = high-sensitive cardiac troponin T; IVS
= interventricular septum; LA = left atrium; LGE = late gadolinium enhancement; LV = left ventricle; NYHA = New York Heart Association; RV =
right ventricle
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Figure 2
Kaplan-Meier analysis for estimation of event-free survival according to elevated (red line) or normal (blue line) hs-cTnT levels. Although
patients with raised hs-cTnT levels showed a trend towards more events, it did not reach statistical significance (p = 0.16).
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